Medical network - September 18 September 16, is "the Chinese brain health day", along with the accelerating pace of life, some of the symptoms associated with brain health, such as headaches dizziness, neurasthenia, cerebrovascular accident, increasingly prominent problems such as stroke, stroke, dementia, more and more people are beginning to realize that the severity of brain health problems. The importance of the drug market in the field of brain health has been highlighted.
Cerebrovascular disease is a brain lesion that occurs in the brain's blood vessels due to various cerebral vascular diseases. According to the world health organization survey, there are nearly 7 million patients with cerebrovascular disease in China, with an annual growth rate of 8.7%. Currently, medical research on brain health focuses on cerebral blood vessels, alzheimer's disease, epilepsy, mental retardation and other typical diseases. Of all the diseases, the disability rate of cerebrovascular disease is the highest, and more than 70% leave all kinds of sequelae. With the rapid increase of the incidence of cerebrovascular disease, cerebral neuroprotective agents have gradually become a popular drug in clinical use.
From the perspective of sales, the market of brain neuroprotective agents has changed significantly, and the growth rate of CAGR was 33.3% from 2005 to 2014. The growth rate of the market in 2015-2016 has slowed down, with an average annual growth rate of less than 7%. Using the data of the sample hospital, we combed the 17 chemical products of the market share of the brain neuroprotective agent from 2005 to 2016.
Figure 1. Sales and growth rate of the sample hospital of cerebral neuroprotective agent from 2005 to 2016 (unit: billion yuan)
Table 1 the sales and growth rate of the main product samples of brain nerve protection agent in 2015 and 2016
The first echelon is over 1 billion yuan
Monosialic acid tetrasinogyrin, olatasan, rat nerve growth factor
According to the statistics of the sample hospital, the total amount of the drug in the 2016 ganglioside fat, olatasan and rat nerve growth factor was 4.36 billion yuan, accounting for 44.6 percent of the market for the drug administration of the brain nerve protection agent. Among them, the sales volume of ganglioside fat was 1.81 billion yuan, down 1.1% from the same period. Sales in olathe were 1.43 billion yuan, up 7.3 percent over the same period. The sales of mouse nerve growth factor were 1.13 billion yuan, up by 17.0% over the same period. The growth rate of rat nerve growth factor exceeded 10.0% and showed good growth. Ganglioside fat has been declining.
Figure 2. Key product sales situation of the first echelon of cerebral nerve protection agent from 2005 to 2016 (unit: billion yuan)
Ganglioside production enterprises have eight sample hospitals, 2016 in the top three companies are: qilu pharmaceutical (market accounted for 63.6%, similarly hereinafter), heilongjiang Harbin university's pharmaceutical industry (8.6%), Beijing pharmaceutical industry (7.6%). The top three companies account for 79.8% of the company, among which qilu has been dominant for years and other companies have struggled to shake.
Olathe temple production enterprises have six sample hospitals, 2016 in the top three companies are: shiyao group, the Italian pharmaceutical (market accounted for 38.7%, similarly hereinafter), guangdong pharmaceutical industry (29.2%), the letter has three Harbin pharmaceutical industry (22.5%). The first three companies accounted for 90.4% of the total, forming a three-way situation.
Mouse nerve growth factor production enterprises have four sample hospitals, 2016, the top three companies are: cable car glides god (Beijing) biological pharmaceutical (market accounted for 40.2%, similarly hereinafter) road biological engineering, xiamen university (30.2%), hubei wuhan hite biopharmaceutical (20.3%). First three companies accounted for 90.7% of the share, the rest of the market occupied by group method method pharmaceutical factory, the company products listed "recreation", broke the mouse nerve growth factor "three kingdoms", has occupied a place in the market.
The second tier is 500 million to 1 billion yuan
The calf blood was extracted from the protein extract, edaravin, cerebroside muscle peptide, butylphthalein, vinpocetine, and cinepazide
Hospital according to the sample data statistics, in 2016 the calf blood protein extracts, pursuant to the adr, brain glycosides carnosine, butyl phthalide, vinpocetine, cassia pp qi drug purchasing medicine amounted to RMB 4.23 billion, accounting for 43.2% of the cranial nerve protectant drug market. Among them, the sales of calf blood protein extract was 9.3 billion yuan, down 16.5% from the same period. The sales volume of edala was 7.7 billion yuan, up 16.1% over the same period. The sales of brain glycine peptide were 7.7 billion yuan, a 7.6 percent increase over the same period. Tphthalein sales were 6.9 billion yuan, up 27.8% over the same period. Changchun xiting sales volume was 540 million yuan, up 6.2 percent from the same period. The sales volume of kwai pieter was 530 million yuan, a 5.5 percent increase over the same period. Among these varieties, the fastest growth of butadiphthalein was the fastest and the most rapid decline in the protein extract of the calves, and the other products increased to varying degrees.
Figure 3. Sales situation of major products of the second echelon of cerebral nerve protection agent from 2005 to 2016 (unit: billion yuan)
Calf blood to protein extract production enterprises there are 10 sample hospitals, 2016 in the top three companies are: jinzhou Mr Hong pharmaceutical industry (market accounted for 77.9%, similarly hereinafter), heilongjiang river the pharmaceutical industry (7.7%), Harbin SAN tai pharmaceutical (5.7%). The top three companies accounted for 91.3 percent of the total, and the mavs blood of jinzhou ohong pharmaceutical co., was the market share of nearly 80%.
Pursuant to the adr production enterprises have entered a sample hospital 12, 2016, the top three companies are: nanjing first sound east yuan pharmaceutical (market accounted for 52.5%, the same below), jilin pharmaceutical (14.1%), and its broad group, the pharmaceutical industry (6.6%). The first three companies accounted for 73.2 percent of the total. Among them, the first dongyuan pharmaceutical company in nanjing, which owns half of the company, has maintained a fast growth rate since it went public.
In 2016, the sales of jilin sihuan pharmaceutical products were 630 million yuan, and the market share was 82.3%. The sales of jilin's four long pharmaceutical products were 140 million yuan, or 17.7 percent.
Tphthalein is the exclusive national variety, the national 1.1 class innovative medicine, is the stone medicine group enbip pharmaceutical industry. In 2016, the sales of tphthalein sample hospital was 660 million yuan, up 27.8% from the same period. The product has two forms of soft capsule and injection, which were listed in 2005 and 2010 respectively. In 2009, soft capsules were included in the national health insurance, and in 2017, the injection form was also included in the national health insurance. Tphthalein sales are growing at a considerable rate, and there is still a lot of room for market development compared with the huge market size of domestic stroke.
Vinpocetine production enterprises have entered a sample hospital, 22, 2016, the top three companies are: henan embellish hong pharmaceutical (market accounted for 69.0%, the same below), Gedeon Richter (21.3%) and hebei wisdom with biological pharmaceutical (3.2%). The manufacturers are numerous, the competition is more intense, the first three enterprises account for 93.5%, have the absolute advantage. Among them, henan runhong pharmaceutical occupies nearly 70% market share. The domestic vinpocetine injection was originally developed by the Beijing honghui pharmaceutical factory. It was transferred to henan runhong pharmaceutical co., LTD. In 2005. The product is named "runtan" and is now growing strongly.
Guangxi pp together, a total of 3 companies to participate in market competition at present, Beijing sihuan pharmaceutical (market accounted for 90.3%, similarly hereinafter) has a ninety percent share, qilu pharmaceutical (6.3%), fujian jinshan biotechnology (3.5%) of the two companies, due to the time of entering the market late, only 10.0% of the market.
The third tier is 50 million to 500 million yuan
Cytophosphine, donnepiazil, hydrolysate of brain protein, farshudiel, dollar gang, compound cerebropeptides, ebenzoquinone and eurekine
Figure 4. Key product sales situation of the third echelon of cerebral nerve protection agent from 2005 to 2016 (unit: billion yuan)
There were 4 production enterprises in the sample hospital and nearly 30 injection agents. In 2016, the market share of qilu pharmaceutical capsule was 37.9%. Szechuan palace pharmaceutical co., jinan limin pharmaceutical and fujian mindong li xun pharmaceutical co., 3 enterprises, accounting for 36.8%. Injections accounted for 25.3%. Among them, qilu pharmaceutical "think forest" occupies a big advantage, this product since 2009 entered the national health insurance catalog, the growth rate is very obvious.
Many production enterprises, pp together into the sample hospitals, chennai, there are 12, 2016, the top three companies are: eisai (China) pharmaceutical industry (market accounted for 90.2%, similarly hereinafter), jiangsu howson pharmaceutical industry (4.0%), shandong rossing pharmaceutical industry (1.3%). The "anrishen" of weiye (China) pharmaceutical industry has been occupying nearly 90% market share, and in 2009, donepericai entered the national health insurance directory and maintained a relatively fast growth rate.
Brain protein hydrolysate production enterprises have entered a sample hospital 14, 2016, the top three companies are: sanlian Harbin pharmaceutical (market accounted for 21.6%, similarly hereinafter), heilongjiang river the pharmaceutical industry (19.9%), jilin wantong pharmaceutical industry (17.7%). The top three accounts for the enterprise market compared to equilibrium, among them, the sanlian Harbin pharmaceutical falling faster than during the same period markets, heilongjiang river pharmaceutical co., jilin wantong pharmaceutical is rose by nearly 20.0%, the market performance is better.
Method of shu, taken into the sample hospitals production enterprises have 13, 2016, the top three companies are: tianjin red sun pharmaceutical industry (market accounted for 45.2%, similarly hereinafter), shanxi buder pharmaceutical industry (20.9%), Wu Hanqi pharmaceutical industry (14.6%). Tianjin hongri has consistently topped the market, but sales have fallen faster than the same period.
The U.S. dollar has just two production enterprises, and the foreign company h. Lumdbeck has the absolute advantage. The market share in 2016 was 98.0%. Zhuhai federal pharmaceutical entered the market late, market share is small.
In 2016, the sales volume of the sample hospital was 7602 million yuan, up 164.8 percent from the same period, and the market performance was more prominent.
There are only two production companies in aidiphenaquinone, and qilu has been able to stay in the top and maintain a fast growth rate. In 2016, the market share of qilu pharmaceutical market was 68.5%, while shenzhen haiwang pharmaceutical accounted for 31.5%.
Eureklin is the exclusive product for guangdong tianpu biochemical medicine. In 2016, the sales volume of sample hospital was 665.3 million yuan, up 12.0% over the same period.
Summary < < <
As China's aging population increases and people's health awareness increases, the number of patients with cerebral vascular disease is expanding, and the market for cerebrovascular drugs market and the brain protection agent market will gradually increase. From the medication of cerebrovascular disease, the neuroprotective agent with chemical medicine is still the mainstream of the market.
Currently, there are many products in the brain neuroprotective agent which involve auxiliary medicine. With the increasing pressure of health insurance control fee, it is imperative to support the medicine strictly, and the winter of auxiliary medicine has been quietly approaching. In the long run, the domestic pharmaceutical market will eventually go to the reasonable standard, and auxiliary medicine will return to reasonable application.
|
